The Bachelor's Sean Lowe Reveals Final Two






The Bachelor










02/25/2013 at 10:30 PM EST







From left: AshLee, Lindsay and Catherine


Kevin Foley/ABC(3)


And then there were two.

After three incredible dates in Thailand with the remaining women, The Bachelor's Sean Lowe faced a difficult decision at the end of Monday's episode: Would he send home AshLee, Catherine or Lindsay?

Keep reading to find out who got a rose – and who was left heartbroken ...

Sean said goodbye to early favorite AshLee in a surprising elimination that left her virtually speechless.

Visibly upset, AshLee left Sean's side without saying goodbye. She even asked him to not walk her to the waiting car that would take her away.

But Sean did get to explain. "I thought it was you from the very beginning," he said. "This was honestly the hardest decision I've ever had to make ... I think the world of you. I did not want to hurt you."

"This wasn't a silly game for me," AshLee said as the car drove away. "This wasn't about a joy ride. It wasn't about laughing and joking and having fun."

She added: "It's hard to say goodbye to Sean because I let him in ... It's the ultimate [rejection]."

Check back Tuesday morning for Sean Lowe's blog post to read all about his Thailand dates and why he chose to send AshLee home

Read More..

Former Cudahy councilman gets 3 years in extortion case









A former Cudahy councilman was sentenced Monday to three years in federal prison for his role in an extortion and bribery case that authorities say exposed widespread corruption in the southeast Los Angeles County city.


Osvaldo Conde is the last of three officials to be sentenced in the federal case. U.S. Atty. Joseph Akrotirianakis recommended that Conde receive seven years in prison.


"We sought a higher sentence for him because he was the leader of the criminal activity in which all defendants were involved," Akrotirianakis said.





But as in the cases of two other Cudahy officials, U.S. District Judge Manuel Real ignored the federal prosecutor's sentencing recommendations.


Last month, former Mayor David Silva, 62, was sentenced to one year in prison, far less than the 41-month term federal prosecutors recommended. Angel Perales, Cudahy's former head of code enforcement and acting city manager, was sentenced to five years' probation. Akrotirianakis had recommended that Perales serve two years in prison.


"I would have liked Mr. Conde to get less time, but I'm relieved that the court didn't follow the government's sentencing," said Conde's attorney, George Bird. "It's neither a celebration nor the end of the world."


Like Silva and Perales, Conde is also required to pay restitution for his part in taking $17,000 in bribes from a man who wanted to open a medical marijuana dispensary in the city.


According to federal documents, all three were caught agreeing to take the money from an FBI informant claiming to want to open a medical marijuana dispensary. The FBI recorded telephone calls and face-to-face conversations with the former city officials.


In their plea agreements, the three portrayed Cudahy as a town where corruption was rampant among those wanting to do business with the city, where elections were rigged and where drugs were used at City Hall.


Court documents lay out a long list of people, usually identified only by their initials, involved in questionable acts. Akrotirianakis said the investigation is ongoing.


ruben.vives@latimes.com





Read More..

India Ink: A Conversation With: Author and Mathematician Manil Suri

The Indian-American author Manil Suri made a splashy entry into the world of writing in 2001 with “The Death of Vishnu,” which became a best seller and was a finalist for the prestigious PEN/Faulkner award. “The Age of Shiva” followed seven years later. This month, the 53-year-old mathematics professor, who teaches at the University of Maryland, Baltimore County, released “The City of Devi,” the final part of a trilogy linked to Hindu gods.

The story is set in a fictional present-day Mumbai, which is in complete disarray because of the threat of a nuclear attack from Pakistan. Residents are leaving the city in droves and police officers are beating people suspected of being Muslims. In the middle of this chaos is Sarita, a recent statistics graduate on a hunt to find her husband, Karun, who disappeared from their apartment.

During her journey, she meets an enigmatic man named Jaz who, unbeknownst to her, is her husband’s former lover. The fast-paced novel cuts between Karun and Sarita’s past lives and the present.

Mr. Suri, who was raised in Mumbai, was in New York City recently to promote the book. He spoke with India Ink about his Kemps Corner upbringing, his slow writing process and his latest work.

What was the inspiration for “The City of Devi”?

It came from the idea of thinking about people who are desperate and willing to take risks to recover a love of theirs as the world might come to an end.

The novel has rich descriptions of the city. How much time did you spend there researching it?

Since I left Bombay, I go back once or twice a year for a few weeks. This book has been in the making for 12 years so I have researched a little bit on each trip.

Tell us about your Mumbai upbringing.

I grew up Kemps Corner and lived in an old crumbling building. I am an only child, and since we were a middle-class family, my parents and I rented one room in a four-bedroom flat which wasn’t so nice. The other three bedrooms were rented by Muslims, and we all shared a toilet and kitchen. I went to Campion school and was around a lot of rich kids so I used to spend a lot of time on my own studying, painting and writing.

You have significant gaps between your books – seven years from the first to the second, and five years for this one. Why did you wait so long between books?

Well, for starters, I am a slow writer. The first book took me five years to write, and the second book took seven years. It was difficult the second time because there was this expectation of following up from the first book, and the pressure was intense. This third book was most difficult in terms of getting the plot strands to behave. I literally drew diagrams plotting the characters and their paths, and I nearly gave up on it twice.

Being a math professor and writer seem like opposite fields. Did both always interest you?

I was always interested in both, but when I was growing up, I was pushed more toward sciences and math. I ended up going into math but used to write as a hobby.

Have you ever contemplated giving up your math career to be a full-time novelist?

I tussled with the idea after the first book and even took time off from teaching just to write but found it wasn’t a good choice for me. I didn’t like being alone all the time, and I missed the math — there was a muscle in the brain that wasn’t exercised enough just by writing.

Like the character Jaz in the book, you’re openly gay. Has that always been the case?

My coming out was around the early 1980s. I came to this country and wasn’t sure if I was or wasn’t but started exploring that side of me.

How did your family take it when you told them?

I came out to my mother first, and she took it fairly well. She has a master’s in psychology so she might have had inklings of it. She has since come and stayed with me and my partner and treats him like a son. She even calls him beta.

What’s your feeling on how the acceptance of homosexuality has evolved in India?

I can’t speak for the villages, but I think the environment has changed when it comes to English-speaking middle-class and upper middle-class people living in cities. I don’t think Mumbai was homophobic when I was growing up. I just think that homosexuality wasn’t talked about, which isn’t the case today.

I was just in India promoting this book, and when I went to Kolkata, I was told not to read out loud the homosexual scenes because it is such a conservative city, and, of course, that’s exactly what I did. No one fainted or walked out, so it turned out okay. I read the same scenes in every city I visited, and the audience was fine with it.

This book is part of a trilogy named after Hindu gods. Now that it’s done, what’s next for you?

My next challenge is to combine math and writing by writing a novel about math. I also have some guilt that I cheated Brahma out of his book by naming this one after the mother goddess so I might write a book named after him.

(The interview has been lightly edited and condensed.)


This post has been revised to reflect the following correction:

Correction: February 25, 2013

An earlier version of the post misstated that Malin Suri is a professor at the University of Maryland. He teaches at the University of Maryland, Baltimore County.

Read More..

Relive the Best One-Liners and Tweets from the Oscars!









02/25/2013 at 12:00 AM EST



Jennifer Lawrence tumbled – to a standing ovation. Ben Affleck tearfully won Best Picure for Argo. And you all loved – or loved to hate – Oscar host Seth MacFarlane.

Yep, the Oscars are over, but it doesn't mean we're done talking about it! You can relive the best of the night! Check out what celebs, readers (and you!) had to say about the musical numbers, speeches – and a certain reigning Sexiest Man Alive! – on Twitter last night.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Mahony answers questions under oath about clergy sex abuse cases









A "relatively unflappable" Cardinal Roger Mahony answered questions under oath for more than 3 1/2 hours Saturday about his handling of clergy sex abuse cases, according to the lawyer who questioned the former archbishop.


"He remained calm and seemingly collected at all times," said attorney Anthony De Marco, who represents a man suing the Los Angeles Archdiocese over abuse he alleges he suffered at the hands of a priest who visited his parish in 1987.


Mahony has been deposed many times in the past, but Saturday's session was the first time he had been asked about recently released internal church records that show he shielded abusers from law enforcement.





De Marco declined to detail the questions he asked or the answers the cardinal provided, citing a judge's protective order.


The deposition occurred just before Mahony was to board a plane for Italy to vote in the conclave that will elect the next pope. In a Twitter post Friday, Mahony wrote that it was "just a few short hours before my departure for Rome."


Church officials did not return requests for comment.


The case, set for trial in April, concerns a Mexican priest, Nicholas Aguilar Rivera. Authorities believe he molested at least 26 children during a nine-month stay in Los Angeles.


Recently released church files show Aguilar Rivera fled to Mexico after a top Mahony aide, Thomas Curry, warned him that parents were likely to go the police and that he was in "a good deal of danger." Aguilar Rivera remains a fugitive in Mexico.


The archdiocese had agreed that Mahony could be questioned for four hours about the Aguilar Rivera case and 25 other priests accused in the same period. De Marco said he did not get to ask everything he wanted and would seek additional time after the cardinal returned from the Vatican.


Past depositions of Mahony have eventually become public, and De Marco said he would follow court procedures to seek the release of a transcript of Saturday's deposition.


Meanwhile, a Catholic organization Saturday delivered a petition with thousands of signatures asking that Mahony recuse himself from the conclave in Rome.


The group, Catholics United, collected nearly 10,000 signatures making "a simple request" that the former archbishop of Los Angeles not participate in the process because of the priest abuse scandals that happened under his watch, said Chris Pumpelly, communications director for Catholics United.


The petition was delivered Saturday to St. Charles Borromeo in North Hollywood, where the cardinal resides. It was accepted by a church staff member.


After delivering the petition, organizers attended Mass at the parish to pray for healing and for the future of the church.


harriet.ryan@latimes.com


Times staff writer Rick Rojas contributed to this report.





Read More..

Insurgents Launch 4 Attacks in Afghanistan







KABUL — Afghan intelligence agents on Sunday shot and killed a man in a sport utility vehicle that officials said had been packed with explosives, foiling what they described as an attempt to set off a massive explosion in a neighborhood of narrow streets lined with foreign embassies.




At about the same time, Taliban suicide attackers set off three separate car bombs in two provinces near the capital. But the bombs did minimal damage,  officials said, and the toll from the Sunday violence was low. In addition to the two attackers and the suspect, two security guards and a police officer were also killed and five other people wounded, including one attacker who managed to flee.


A spokesman for the Taliban, Zabiullah Mujahid, said the insurgents were behind the three successful bombings. But he disavowed knowledge of the attempt in Kabul, saying Taliban commanders in the city had no plans for an attack on Sunday.


While it is not unusual for the Taliban to deny having a hand in a failed attack, much about the attempted bombing Sunday remained murky, with officials hailing Afghan security forces for acting quickly but offering only the barest details about how the man identified as a bomber was spotted.


The police chief of Kabul, Gen. Mohammed Ayoub Salangi, said the suspect was in a Toyota sport utility vehicle and was trying to pass through a checkpoint when he was recognized by agents from the country’s intelligence service, the National Directorate of Security.


The man “was gunned down,” General Salangi said. The agents had to act quickly, he added, saying that there was no time to inspect the vehicle or question the suspect because that would have given him the chance to detonate the explosives.


General Salangi, who in an earlier statement said there were two men in the car, did not say how or why the agents recognized the man. But he added that the car bomb was quickly defused and carted away.


The bombing attempt, in the Wazir Akbar Khan neighborhood, led some embassies to did briefly lock down the streets on which they are located and on which they control security. The spot where the man was shot were was less than a mile from the United States Embassy and the headquarters of the American-led coalition, neither of which offered any comment.


Earlier in the day, in Jalalabad, a city in eastern Afghanistan, a single bomber in a Toyota Corolla directly targeted the Security Directorate, officials said, detonating his explosive-laden vehicle outside a building used by the intelligence agency. Two guards were killed and a third was wounded, said Hazrat Mohammad Mashraqiwal, a police spokesman in Jalalabad.


Later on Sunday, two people in another car laden with explosives tried to enter the district governor’s compound in Baraki Barak district of Logar Province, south of Kabul. But they were stopped by police officers guarding the compound, prompting one man to jump and make a run for it and the other to set off the car bomb, said Abdul Rahim Amin, the governor.


One police officer was wounded in the attack, along with the man who fled.


Earlier in Logar, around dawn, a minivan packed with explosives was set off at a police post near the provincial capital, Pul-e-Alam. One officer was killed and two others wounded, an official said.


Sharifullah Sahak contributed reporting.


Read More..

See the Mini Balenciaga Bag Kim Kardashian Gifted Niece Penelope




Celebrity Baby Blog





02/22/2013 at 05:00 PM ET



Mom Kourtney Kardashian has one! Aunts Kim and Khloé own one too. And now Penelope Disick is the latest family member to add Balenciaga‘s chic city tote to her closet.


“Penelope is wearing the little Balenciaga bag that I got her for Christmas!” Kim posted on Instagram Friday, along with an adorable photo of the mom-to-be with her 7½-month-old niece and her mini yellow handbag.


Is Kim gearing up for her little one? If she has a little girl, we have no doubt her wardrobe will be the envy of the playground. Although the expectant reality star recently revealed that if it’s up to dad-to-be Kanye West, their baby will be wearing lots of “big chains and leather pants.”


And to be fair, Penelope wasn’t the only Kardashian-Jenner kid to receive luxe fashions for Christmas. Kylie and Kendall also scored during the holidays.


Kim Kardashian, Penelope Disick and Her Mini Balenciaga Bag
Courtesy Kim Kardashian; Inset: Rex USA



– Shanelle Rein-Olowokere


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Paroled sex offenders disarming tracking devices









SACRAMENTO — Thousands of paroled child molesters, rapists and other high-risk sex offenders in California are removing or disarming their court-ordered GPS tracking devices — and some have been charged with new crimes including sexual battery, kidnapping and attempted manslaughter.


The offenders have discovered that they can disable the monitors, often with little risk of serving time for it, a Times investigation has found. The jails are too full to hold them.


"It's a huge problem," said Fresno parole agent Matt Hill. "If the public knew, they'd be shocked."





More than 3,400 arrest warrants for GPS tamperers have been issued since October 2011, when the state began referring parole violators to county jails instead of returning them to its packed prisons. Warrants increased 28% in 2012 compared to the 12 months before the change in custody began. Nearly all of the warrants were for sex offenders, who are the vast majority of convicts with monitors, and many were for repeat violations.


The custody shift is part of Gov. Jerry Brown and the legislature's "realignment" program, to comply with court orders to reduce overcrowding in state prisons. But many counties have been under their own court orders to ease crowding in their jails.


Some have freed parole violators within days, or even hours, of arrest rather than keep them in custody. Some have refused to accept them at all.


Before prison realignment took effect, sex offenders who breached parole remained behind bars, awaiting hearings that could send them back to prison for up to a year. Now, the maximum penalty is 180 days in jail, but many never serve that time.


With so little deterrent, parolees "certainly are feeling more bold," said Jack Wallace, an executive at the California Sex Offender Management Board.


Rithy Mam, a convicted child stalker, was arrested three times in two months after skipping parole and was freed almost immediately each time. After his third release, his GPS alarm went off and he vanished, law enforcement records show.


The next day, he turned up in a Stockton living room where a 15-year-old girl was asleep on the couch, police said. The girl told police she awoke to find the stranger staring at her and that he asked "Wanna date?" before leaving the home.


Police say Mam went back twice more that week and menaced the girl and her 13-year-old sister, getting in by giving candy to a toddler, before authorities recaptured him in a local park. He is in custody on new charges of child molestation.


Californians voted in 2006 to require that high-risk sex offenders be tracked for life with GPS monitors strapped to their bodies.


The devices are programmed to record offenders' movements and are intended, at least in part, to deter them from committing crimes. The devices, attached to rubber ankle straps embedded with fiber-optic cable, transmit signals monitored by a private contractor.


They are easy to cut off, but an alarm is triggered when that happens, as it is when they are interfered with in other ways or go dead, or when an offender enters a forbidden area such as a school zone or playground. The monitoring company alerts parole agents by text message or email.


Arrest warrants for GPS tamperers are automatically published online. The Times reviewed that data as well as thousands of jail logs, court documents and criminal histories provided by confidential sources. The records show that the way authorities handle violators can vary significantly by county.


San Bernardino County releases more inmates early from its cramped jails than any other county in California, according to state reports. But sex offenders who violate parole there generally serve their terms. A spokeswoman said the county closely reviews criminal histories, and those with past sex offenses are ineligible for early release.


By contrast, parole violators in San Joaquin County are often set free within a day of arrest.


A review of the county's jail logs shows that nine of the 15 sex offenders arrested for violating parole in December and January were let out within 24 hours, including seven who immediately tampered with their trackers and disappeared. One of the nine, a convicted rapist named Robert Stone, was arrested two weeks later on kidnapping charges and returned to jail, where he remains.


Raoul Leyva, a sex offender with a history of beating women, was arrested in April for fleeing parole and ordered to remain jailed for 100 days. He was out in 16 days and soon bolted again, after allowing the battery on his device to go dead, according to the documents reviewed by The Times.


Less than two weeks later, a drug dealer led police to a Stockton apartment where Leyva's girlfriend, 20-year-old Brandy Arreola, had lain for days on the floor, severely beaten and in a coma. Now brain damaged and confined to a wheelchair, Arreola spends her time watching cartoons.





Read More..